

bs-0015R**[Primary Antibody]****IGF2 Rabbit pAb****Bioss**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

— DATASHEET —


Host: Rabbit Clonality: Polyclonal GeneID: 3481 Target: IGF2 Immunogen: KLH conjugated synthetic peptide derived from human IGF2: 25-51/180. Purification: affinity purified by Protein A Concentration: 1mg/ml Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. Background: The IGF2 gene encodes a member of the insulin family of polypeptide growth factors that is involved in development and growth. It is expressed only from the paternally inherited allele and is an imprinted gene which is a candidate gene for eating disorders. There is a read-through, INS-IGF2, which aligns to this gene at the 3' region and to the upstream INS gene at the 5' region. Two alternatively spliced transcript variants encoding the same protein have been found for this gene. Insulin Like Growth Factor-2 (IGF-2) is a polypeptide growth factor, which stimulates the proliferation of a wide range of cell types.	Isotype: IgG SWISS: P01344	Applications: IHC-P (1:100-500) IHC-F (1:100-500) IF (1:100-500) Flow-Cyt (1 μ g/Test) Reactivity: Human, Rat (predicted: Mouse, Rabbit, Pig, Sheep, Cow, Dog) Predicted MW.: 7.4 kDa Subcellular Location: Secreted
---	---	--

— VALIDATION IMAGES —

Tissue/cell: rat placenta tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Incubation: Anti-IGF II Polyclonal Antibody, Unconjugated (bs-0015R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody (SP-0023) and DAB (C-0010) staining



Paraformaldehyde-fixed, paraffin embedded (Rat liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (IGF II) Polyclonal Antibody, Unconjugated (bs-0015R) at 1:400 overnight at 4°C, followed by operating according to SP Kit (Rabbit) (sp-0023) instructions and DAB staining.



Blank control: HepG2. Primary Antibody (green line): Rabbit Anti-IGF II antibody (bs-0015R) Dilution: 1 μ g /10⁶ cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-AF647 Dilution: 1 μ g /test. Protocol The cells were fixed with 4% PFA (10min at room temperature) and then permeabilized with 0.1% PBST for 20 min at room temperature. The cells were then incubated in 5% BSA to block non-specific protein-protein interactions for 30 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

— SELECTED CITATIONS —

- **[IF=5.162]** Lei Zhao. et al. Proteomic analysis reveals the molecular mechanism of Hippophae rhamnoides polysaccharide intervention in LPS-induced inflammation of IPEC-J2 cells in piglets. Int J Biol Macromol. 2020

Dec;164:3294 WB ;Pig. 32888998

- **[IF=4.932]** Qingyu Meng. et al. Morin hydrate inhibits atherosclerosis and LPS-induced endothelial cells inflammatory responses by modulating the NFκB signaling-mediated autophagy. Int Immunopharmacol. 2021 Nov;100:108096 WB ;Human. 34464886
- **[IF=4.5]** Changbin Zhao. et al. IGF2 promotes the differentiation of chicken embryonic myoblast by regulating mitochondrial remodeling. J CELL PHYSIOL. 2024 Jun;: WB ;Chicken. 38946060
- **[IF=2.426]** Yuanyuan Wang. et al. Role of AURKA in the hypothalamus–pituitary–testicular axis in Tibetan sheep from Tianzhu. Gen Comp Endocr. 2021 Jan;300:113617 WB ;Sheep. 32950578
- **[IF=0]** Ma Y et al. Promotion of Insulin-like growth factor II in cell proliferation and epithelial–mesenchymal transition in hepatocellular carcinoma. J Cancer Res Ther. 2018;14(4):844-850. WB ;Human. 29970663